Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib plus chemotherapy for GI tumors with liver metastases
NCT05262335Phase 2Unknown
- Sponsor
- Ruijin Hospital
- Start
- Dec 2021
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of anlotinib in gastrointestinal tumor, colorectal cancer (CRC), Esophageal Squamous Cell Carcinoma (ESCC), liver metastases, sponsored by Ruijin Hospital. Status: unknown.
02
Drugs
anlotinib
03
Conditions
gastrointestinal tumorcolorectal cancer (CRC)Esophageal Squamous Cell Carcinoma (ESCC)liver metastases
Beyond the preview
Go deeper on NCT05262335.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05262335.